A study to investigate the effect of lepodisiran on the occurrence of major adverse cardiovascular events (MACE) in adults with elevated Lp(a) and atherosclerotic cardiovascular disease (ASCVD) or at risk of a first CV event
Educational Partners and Supporters
AstraZeneca has provided a sponsorship grant towards this independent programme.
